Recombinant cytomegalovirus vectors as vaccines for tuberculosis
US11834669B2 · kind B2 · utility
0Cited by
31References
23Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 1, 2021 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Jul 1, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.